Novo Nordisk makes the world's leading diabetes and obesity drugs, including blockbuster GLP-1 treatments like Ozempic and Wegovy, plus insulin pens and rare-disease therapies.
Money comes from selling prescription medicines, mainly diabetes and obesity drugs, with recurring revenue from chronic-use patients. Gross margin is 80.65% and net margin 35.35%, showing highly profitable, sticky sales.
Hard-to-replicate manufacturing know-how, patent protection, and a massive installed base of patients and doctors create a durable edge. But Eli Lilly's competing GLP-1 drugs and looming patent expiries are actively eroding that advantage.
Hold (sector percentile 50) — value A, growth C, profitability A, momentum D, revisions C. Updated daily, sector-relative, identical for every user.
Key events, in time order
New study tests lower doses, potentially expanding oral weight-loss drug access
Eli Lilly's Foundayo, Europe's first oral GLP-1 approval with no food restrictions, directly challenges Novo Nordisk's oral Wegovy
Analyst sees further multiple expansion requiring proof of obesity-pill lead and injectable growth
Institutional selling signals caution on Novo Nordisk's near-term outlook.
Earnings call reveals latest results, completing the event line with prior guidance and stock reaction
Lilly reports 28.3% average weight loss over 80 weeks in phase 3, with official filing timeline, directly pressuring Novo Nordisk
Federal judge dismisses Strive antitrust suit; NVO rises nearly 2%
Dutch court ruled in favor of Novo Nordisk in patent infringement case against Ceban Ziekenhuisfarmacie.
Lilly's early access move raises questions on which pathway wins mass market.
Citi keeps neutral, sees selloff overdone but GLP-1 worries cap upside.
Analysts cut ziltivekimab PoS to 40%, launch expected 2028E
Ziltivekimab failed to improve cardiovascular outcomes, but company maintains 2026 guidance and continues two additional trials.
Multiple analysts raise ratings/PTs on oral Wegovy rapid uptake
Social media claims 170K total prescriptions for oral Wegovy, with Lilly far behind; single source, treat cautiously
After suing Lilly over misleading ads, Novo seeks preliminary injunction, escalating legal action.
Citi lifts target to DKK330 citing strong oral Wegovy launch, reinforcing product momentum
Partners with Acino to launch authorized copy, improving access
South Africa approves Sun Pharma's generic semaglutide, potential market impact
Adjusted sales decreased 4% in Q1 2026, driven by lower realized prices partly offset by GLP-1 volume growth and market expansion
None yet
None yet
Novo Nordisk is discussed as a growth company with potential for future gains, driven by the expansion of its oral Wegovy treatment market. The conversation includes position statements and stock recommendations.
Main discussion
When investing if you focus on growth companies with concentrated multiples you will have a high hit rate! This is why I bought: $HIMS- $20 $SOFI- $7 $ZETA- $17 Here are stocks I would look at now: $APP- $300 $SOFI-$19 $NVO- $46
RT @Investinc_Intel: ORAL WEGOVY TREATMENT WILL CONTINUE TO UNLOCK A WHOLE NEW MARKET! $HIMS $NVO https://t.co/Uei4f6Fzlw
I have done this with $HIMS $PLTR $ZETA $OSCR $UNH $ETH $BTC $ADUR $ASTS $NBIS And now I’m saying the same for: $SE $NVO $BABA $GRRR $GRAB We know where they are going next Zero doubt.
No comments yet.
Facts and opinions separated · All items sourced · Not investment advice
